ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

HQY

96.3

-0.17%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

HQY

96.3

-0.17%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

HQY

96.3

-0.17%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

HQY

96.3

-0.17%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

HQY

96.3

-0.17%↓

Search

Johnson and Johnson

Geschlossen

BrancheGesundheitswesen

190.31 -0.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

189.55

Max

190.79

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5.5B

5.5B

Verkäufe

250M

24B

KGV

Branchendurchschnitt

18.663

37.461

EPS

2.8

Dividendenrendite

2.63

Gewinnspanne

23.321

Angestellte

138,100

EBITDA

-1.2B

7.5B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+8.44% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.63%

2.33%

Nächste Dividendenausschüttung

9. Dez. 2025

Nächstes Ex-Dividendendatum

25. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

6.8B

467B

Vorheriger Eröffnungskurs

190.46

Vorheriger Schlusskurs

190.31

Nachrichtenstimmung

By Acuity

22%

78%

34 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Johnson and Johnson Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Okt. 2025, 10:35 UTC

Ergebnisse

J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains

14. Okt. 2025, 10:51 UTC

Market Talk
Ergebnisse

J&J Sales Get Boost From Tremfya Drug -- Market Talk

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Raises 2025 View To Sales $93.5B-$93.9B Vs Prior View $93.2B-$93.6B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Now Sees 2025 Operational Sales of $93B-$93.4B Vs Prior Range $92.7B-$93.1B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.5%-4% Vs Prior Outlook 3.2%-3.7% >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Backs 2025 Adj EPS $10.80-Adj EPS $10.90 >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Worldwide MedTech Sales $8.43B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: 3Q MedTech Business Delivered Operational Sales Grew 5.6%, Driven Primarily by Electrophysiology Products, Abiomed, Shockwave, Wound Closure Pdts and Surgical Vision >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: 3Q Innovative Medicine Operational Sales Grew 5.3%, With Net Acquisitions and Divestitures Positively Affecting Growth by 1.6% Due to Caplyta >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q International Sales $10.29B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Still Sees 2025 Adjusted Operational EPS $10.63-$10.73 >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.8%-5.3% Vs Prior Range 4.5%-5% >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: 3Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya, Simponi/Simponi Aria and Spravato >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Adj EPS $2.80 >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Orthopaedics Sales $2.27B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $15.56B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q U.S. Sales $13.71B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Sales $23.99B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q EPS $2.12 >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Orthopaedics Sales $2.27B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q EPS $2.12 >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Worldwide MedTech Sales $8.43B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q U.S. Sales $13.71B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q International Sales $10.29B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $15.56B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Net $5.15B >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Adj EPS $2.80 >JNJ

14. Okt. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 3Q Sales $23.99B >JNJ

14. Okt. 2025, 10:03 UTC

Heiße Aktien

Stocks to Watch Tuesday: JPMorgan, Goldman Sachs, Ford -- WSJ

10. Okt. 2025, 16:19 UTC

Akquisitionen, Fusionen, Übernahmen

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

Peer-Vergleich

Kursveränderung

Johnson and Johnson Prognose

Kursziel

By TipRanks

8.44% Vorteil

12-Monats-Prognose

Durchschnitt 206.47 USD  8.44%

Hoch 225 USD

Tief 176 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Johnson and Johnson – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

19 ratings

12

Buy

7

Halten

0

Sell

Technischer Score

By Trading Central

154.93 / 155.895Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

34 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat